Wu James J, Seco Michael, Medi Caroline, Semsarian Chris, Richmond David R, Dearani Joseph A, Schaff Hartzell V, Byrom Michael J, Bannon Paul G
Sydney Medical School, The University of Sydney, Sydney, Australia.
The Baird Institute of Applied Heart & Lung Surgical Research, Sydney, Australia.
Biophys Rev. 2015 Mar;7(1):117-125. doi: 10.1007/s12551-014-0153-3. Epub 2015 Jan 10.
Hypertrophic cardiomyopathy (HCM) is a genetically determined cardiac disease characterised by otherwise unexplained myocardial hypertrophy of the left ventricle, and may result in left ventricular outflow tract obstruction. It is the most common cause of sudden cardiac death in young adults due to arrhythmias. Septal myectomy is a surgical treatment for HCM with moderate to severe outflow tract obstruction, and is indicated for patients with severe symptoms refractory to medical therapy. The surgical approach involves obtaining access to the interventricular septum via transaortic, transapical or transmitral approaches, and excising a portion of the hypertrophied myocardium to relieve the outflow tract obstruction. Large, contemporary series from centres experienced in septal myectomy patients have demonstrated a low early mortality of <2 %, excellent long-term survival that matches the general population, and durable relief of symptoms.
肥厚型心肌病（HCM）是一种由基因决定的心脏疾病，其特征是左心室出现无法用其他原因解释的心肌肥厚，并且可能导致左心室流出道梗阻。它是年轻成年人因心律失常导致心源性猝死的最常见原因。室间隔心肌切除术是治疗伴有中度至重度流出道梗阻的肥厚型心肌病的一种手术方法，适用于药物治疗难以控制严重症状的患者。手术方式包括通过经主动脉、经心尖或经二尖瓣途径进入室间隔，切除一部分肥厚的心肌以缓解流出道梗阻。来自有室间隔心肌切除术经验的中心的大型当代系列研究表明，早期死亡率低，<2%，长期生存率极佳，与普通人群相当，且症状缓解持久。
